DMGDH
Dimethylglycine dehydrogenase, mitochondrial
Also known as: M2GD_HUMAN, ME2GLYDH
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UI17
- Gene
- DMGDH
- Ensembl
- ENSG00000132837
- Chromosome
- 5
- Canonical length
- 866 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Mitochondria
OverviewNCBI Gene
This gene encodes an enzyme involved in the catabolism of choline, catalyzing the oxidative demethylation of dimethylglycine to form sarcosine. The enzyme is found as a monomer in the mitochondrial matrix, and uses flavin adenine dinucleotide and folate as cofactors. Mutation in this gene causes dimethylglycine dehydrogenase deficiency, characterized by a fishlike body odor, chronic muscle fatigue, and elevated levels of the muscle form of creatine kinase in serum. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
866 residues, UniProt reviewed canonical sequence.
>Q9UI17|DMGDH
1 MLRPGAQLLR GLLLRSCPLQ GSPGRPRSVC GREGEEKPPL SAETQWKDRA ETVIIGGGCV
61 GVSLAYHLAK AGMKDVVLLE KSELTAGSTW HAAGLTTYFH PGINLKKIHY DSIKLYEKLE
121 EETGQVVGFH QPGSIRLATT PVRVDEFKYQ MTRTGWHATE QYLIEPEKIQ EMFPLLNMNK
181 VLAGLYNPGD GHIDPYSLTM ALAAGARKCG ALLKYPAPVT SLKARSDGTW DVETPQGSMR
241 ANRIVNAAGF WAREVGKMIG LEHPLIPVQH QYVVTSTISE VKALKRELPV LRDLEGSYYL
301 RQERDGLLFG PYESQEKMKV QDSWVTNGVP PGFGKELFES DLDRIMEHIK AAMEMVPVLK
361 KADIINVVNG PITYSPDILP MVGPHQGVRN YWVAIGFGYG IIHAGGVGKY LSDWILHGEP
421 PFDLIELDPN RYGKWTTTQY TEAKARESYG FNNIVGYPKE ERFAGRPTQR VSGLYQRLES
481 KCSMGFHAGW EQPHWFYKPG QDTQYRPSFR RTNWFEPVGS EYKQVMQRVA VTDLSPFGKF
541 NIKGQDSIRL LDHLFANVIP KVGFTNISHM LTPKGRVYAE LTVSHQSPGE FLLITGSGSE
601 LHDLRWIEEE AVKGGYDVEI KNITDELGVL GVAGPQARKV LQKLTSEDLS DDVFKFLQTK
661 SLKVSNIPVT AIRISYTGEL GWELYHRRED SVALYDAIMN AGQEEGIDNF GTYAMNALRL
721 EKAFRAWGLE MNCDTNPLEA GLEYFVKLNK PADFIGKQAL KQIKAKGLKR RLVCLTLATD
781 DVDPEGNESI WYNGKVVGNT TSGSYSYSIQ KSLAFAYVPV QLSEVGQQVE VELLGKNYPA
841 VIIQEPLVLT EPTRNRLQKK GGKDKTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against DMGDH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.22
- Highest tissue expression
- 265 nTPM
Expression across tissuesHPA
Tissue
- liver: 265 nTPM
- kidney: 158 nTPM
- epididymis: 12 nTPM
- adipose tissue: 7.9 nTPM
- choroid plexus: 4.8 nTPM
- thyroid gland: 4.5 nTPM
Single-cell type
- hepatocytes: 251 nCPM
- proximal tubule cells: 230 nCPM
- adipocytes: 186 nCPM
- loop of henle epithelial cells: 156 nCPM
- distal convoluted tubule cells: 151 nCPM
- gonadotrophs: 133 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 5.9 nTPM
- hypothalamus: 5.5 nTPM
- midbrain: 3.7 nTPM
- pons: 3.7 nTPM
- basal ganglia: 3.1 nTPM
- thalamus: 3.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about DMGDH.
Disease | AllUniProt
Conditions DMGDH is implicated in, by any mechanism.
- DMGDH deficiency (DMGDHD) MIM:605850
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 192 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Dimethylglycine dehydrogenase deficiency
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.17
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.56
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- electron transfer activity
- RNA binding
- dimethylglycine dehydrogenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- FAD dependent oxidoreductase
- GCVT, N-terminal domain
- Aminomethyltransferase, C-terminal domain
- Aminomethyltransferase superfamily
- Aminomethyltransferase-like
- Glycine cleavage T-protein/YgfZ, C-terminal
- FAD dependent oxidoreductase, central domain
- FAD/NAD(P)-binding domain superfamily
- FAD dependent oxidoreductase
- GCVT N-terminal domain
- Glycine cleavage T-protein C-terminal barrel domain
- FAD dependent oxidoreductase central domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of DMGDH in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads DMGDH as an antibody target. Whether an autoantibody or antibody against DMGDH could matter depends on whether native DMGDH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
DMGDH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label DMGDH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...